North China Pharmaceutical's (SHA:600812) unit, North China Pharmaceutical Group Xiantai, passed the good manufacturing practices or GMP inspection of the drug regulator of China's Hebei Province, according to the company's disclosure on the Shanghai Stock Exchange.
The inspection held between March 18 and March 22 covered the pharmaceutical company's production line, which produced raw drug ingredients such as ampicillin and piperacillin, the Wednesday disclosure added.
Price (RMB): ¥4.96, Change: ¥-0.01, Percent Change: -0.20%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments